Navigation Links
Techne Corporation Announces Acquisition Agreement
Date:6/18/2013

on of closing conditions, the integration of Bionostics into the Techne group of companies, the actual financial results of Bionostics, the purchase price allocation of the acquisition, the introduction and acceptance of new clinical control products, the levels and particular directions of purchases by the Company's customers, the impact of the number of producers of clinical control products and related price competition, general economic conditions, the retention of clinical controls OEM and proficiency survey business, the impact of currency exchange rate fluctuations, and the costs and results of product development efforts of the Company and of companies in which the Company has invested or with which it has formed strategic relationships.  For additional information concerning such factors and additional factors, see the Company's annual report on Form 10-K and quarterly reports on Form 10-Q as filed with the Securities and Exchange Commission.  We undertake no obligation to update or revise any forward-looking statements we make in our press releases due to new information or future events.  Investors are cautioned not to place undue emphasis on these statements.

Techne Corporation has two operating subsidiaries:  Research and Diagnostic Systems, Inc. (R&D Systems) of Minneapolis, Minnesota and R&D Systems Europe, Ltd. (R&D Europe) of Abingdon, England.  R&D Systems is a specialty manufacturer of biological products.  R&D Systems has three subsidiaries:  BiosPacific, Inc. (BiosPacific), located in Emeryville, California, Boston Biochem, Inc., located in Cambridge, Massachusetts, and R&D Systems China Co. Ltd., (R&D China), located in Shanghai, China.  BiosPacific is a worldwide supplier of biologics to manufacturers of in vitro diagnostic systems and immunodiagnostic kits. Bo
'/>"/>

SOURCE Techne Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Techne Corporation Releases Unaudited Third Quarter And Nine Month Fiscal Year 2013 Results
2. US Radiopharmaceuticals (USR) Awards Contract to Von Gahlen International for New Technetium-99m Generator Production Line Using Low Enriched Uranium Molybdenum-99
3. Techne Corporation Declares Dividend And Announces An Increase In Its Share Repurchase Program
4. Techne Corporation Declares Dividend
5. China Cord Blood Corporation to Report Fourth Quarter and Full Year of Fiscal 2013 Financial Results
6. Celsion Corporation Announces $9.83 Million Registered Direct Offering
7. Sigma-Aldrich Corporation Presentations At Three Upcoming Conferences To Be Webcast Live
8. Celladon Corporation Selected as Winner of Red Herrings "Top 100 North America Tech Startup"
9. The Renewable Corporation (RNWB) through its wholly owned subsidiary EcoSmart Surface & Coating Technologies receives results from Product Test Service.
10. Cadwalader Advises Elan Corporation in Billion Dollar Royalty Deal
11. Celsion Corporation Reports First Quarter 2013 Financial Results and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... N.C. , May 29, 2015 ... affairs function into roles involving clinical development, regulatory ... its responsibilities have grown, Medical Affairs has faced ... as a global group. And while its importance ... it challenging to identify strong performance metrics to ...
(Date:5/29/2015)... , May 29, 2015 In recent ... the availability of Big Data that can generate valuable ... come with utilizing Big Data have caused the biopharmaceutical ... other industries. According to a recent ... participants already have a Big Data team or function ...
(Date:5/29/2015)... , May 29, 2015 ... company, today announces that an abstract on the latest ... inhibitor of the Axl receptor tyrosine kinase, and BGB10C9, ... BerGenBio, has been published in conjunction with the 2015 ... Chicago , May 29 - June ...
(Date:5/29/2015)... 2015 GeneWEAVE, Inc ., ... announced that initial feasibility data supporting the use ... susceptibility testing from positive blood cultures will be ... 2015 in New Orleans, LA. The Company’s Smarticles™ ... that can quickly detect bacteria and assess antibiotic ...
Breaking Biology Technology:Creating an Effective Pharmaceutical Medical Affairs Group with Global Capabilities 2New Study Details Current & Future Big Data Trends Across Medical Affairs Functions 2BGB324 and BGB10C9 Show Promise in Models of Pancreatic Cancer 2BGB324 and BGB10C9 Show Promise in Models of Pancreatic Cancer 3Data Highlighting GeneWEAVE’s Smarticles™ Technology to be Presented at the 115th General Meeting of the American Society for Microbiology (asm2015) 2Data Highlighting GeneWEAVE’s Smarticles™ Technology to be Presented at the 115th General Meeting of the American Society for Microbiology (asm2015) 3
... ... , ... October 19, 2009 -- Genedata, a leading provider of in silico solutions for pharmaceutical ... Medicine, Academy of Sciences of the Czech Republic, to study the effects of air ...
... Inc., today announced that the U.S. Food and Drug ... for the first 15 monoclonal antibodies in its proprietary ... use by blood donor centers, reference laboratories, and hospitals ... was formed earlier this year to directly commercialize its ...
... 17 UCB today announced data that showed rapid ... fatigue of rheumatoid arthritis (RA) as early as the ... damage (seen at week 24) following treatment with Cimzia® ... to 100 weeks. Cimzia® is approved for the treatment ...
Cached Biology Technology:Genedata and the Institute of Experimental Medicine, Academy of Sciences of the Czech Republic Collaborate on Asthma Bronchiale Project 2Genedata and the Institute of Experimental Medicine, Academy of Sciences of the Czech Republic Collaborate on Asthma Bronchiale Project 3Genedata and the Institute of Experimental Medicine, Academy of Sciences of the Czech Republic Collaborate on Asthma Bronchiale Project 4Quotient Biodiagnostics Receives U.S. Food & Drug Administration Clearance To Enter U.S. Transfusion Diagnostics Market 2UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 2UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 3UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 4UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 5UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 6UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 7UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 8UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 9UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 10UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 11UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 12
(Date:5/29/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/2w6zgs/facial ) has ... Market by Solution, by Software, by Hardware, by ... report to their offering. The last ... more efficient and cost effective. This has helped ... the commercial sector. The development of 3D facial ...
(Date:5/28/2015)... 2015 Industry analyst firm n-tech Research ... titled "Markets for Self-Healing Materials: 2015-2022." According to the ... vascular systems, biomaterials, relevant shape memory materials and ... billion by 2020. The report is ... smart materials. Other recent n-tech reports have included studies ...
(Date:5/27/2015)...   Codonics (codonics.com), a global ... documentation solutions and Omnicell  (omnicell.com), a ... is pleased to announce their state of ... System® (SLS), an award-winning FDA class 2 ... Anesthesia Workstation, helps prevent medication errors, streamlines ...
Breaking Biology News(10 mins):Global advanced Facial Recognition Market Expected to Grow From $2.77 Billion in 2015 to $6.19 Billion in 2020, at an Estimated CAGR of 17.4% 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 3Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4
... MADISON People get type 2 diabetes. So do cats. ... in the shape of proteins protect some and endanger others. ... it only differs a little bit from species to species," ... mammals that get type 2 diabetes, their amylin proteins aggregate ...
... Energy is making good on the second phase of a plant ... by Dr. Joshua Yuan, Texas A&M AgriLife Research plant pathologist., ... Yuan, who was granted $1.8 million for Phase I by the ... source., The scientist said his research is moving ahead so quickly ...
... the Earth has reached the limits of its biophysical ... and social norms relating to material production and consumption ... functioning of our planet,s life support systems. ... pivotal role to play in this transition. This timely ...
Cached Biology News:New look identifies crucial clumping of diabetes-causing proteins 2Plant fuel project moves to second phase under US Energy Department grant 2